If you liked this article you might like

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views
Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma
Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments
Jim Cramer -- Incyte Stock Is Red-Hot, Worth More Than $200 in a Takeout